Multiple Myeloma Excellence Forum

Multiple Myeloma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Conference Coverage

Role of CD38 Monoclonal Antibodies and Bispecific Antibodies in Treating Multiple Myeloma

02/23/2024

Featuring Ajai Chari, MD

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, shares his insights on the role of CD38 monoclonal antibodies and bispecific antibodies for the treatment of patients with multiple myeloma.

At the Lymphoma, Leukemia &...

02/23/2024

Lymphoma, Leukemia & Myeloma Network

Videos

Strategies for Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

02/13/2024

Suzanne Lentszch , MD, PhD;

At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.

At the 2023 Lymphoma, Leukemia &...

02/13/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

CAR-T Cell Therapy vs Stem Cell Transplant for the Treatment of Patients With Multiple Myeloma

01/24/2024

Adriana Rossi , MD;

During a debate at the 2023 Lymphoma, Leukemia & Myeloma Congress, Adriana Rossi, MD, discussed whether CAR-T therapy is more beneficial than stem cell transplant in treatment regimens among patients with multiple myeloma.

During a debate at the 2023...

01/24/2024

Lymphoma, Leukemia & Myeloma Network

Dan Vogl, MD, University of Pennsylvania

Conference Coverage

Evaluating Bispecific T-Cell Engagers for the Treatment of Patients With Multiple Myeloma

01/23/2024

Dan Vogl , MD;

During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Dan Vogl, MD, discusses the optimal use of newly available bispecific T-cell engagers and other targets for multiple myeloma treatment.

During the 2023 Lymphoma,...

01/23/2024

Lymphoma, Leukemia & Myeloma Network

Faith E. Davies, MD, Perlmutter Cancer Center

Conference Coverage

Choosing a Treatment Strategy for Patients With Early Relapsed Multiple Myeloma

01/22/2024

Faith E. Davies , MD;

During the 2023 Lymphoma, Leukemia & Myeloma Congress, Faith E Davies, MD, discussed current treatment options for patients with early relapsed multiple myeloma.

During the 2023 Lymphoma,...

01/22/2024

Lymphoma, Leukemia & Myeloma Network

Carlyn Rose Tan, MD, Memorial Sloan Kettering Cancer Center

Conference Coverage

Prior Exposure to TCRT Associated With Lower CRS Incidence During Teclistamab Step-Up Dosing Phase Among Patients With R/R MM

01/22/2024

Carlyn Rose Tan , MD;

At the 65th ASH Annual Meeting, Carlyn Rose Tan, MD, presented data that for patients with R/R multiple myeloma, exposure to a T-cell redirection therapy correlated with a lower incidence of cytokine release syndrome during the teclistamab...

At the 65th ASH Annual Meeting,...

01/22/2024

Oncology

Joseph Mikhael, MD, City of Hope Cancer Center

Conference Coverage

Strategies for Treating Patients With Multiply Relapsed Multiple Myeloma

01/19/2024

Joseph Mikhael , MD, MEd, FRCPC;

At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment regimens like CELMoDs and XP01 inhibitors for patients with multiply relapsed multiple myeloma.

At the 2023 Lymphoma, Leukemia &...

01/19/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Benefits of MRD Testing for the Treatment of Patients With Multiple Myeloma

01/19/2024

Joseph Mikhael , MD, MEd, FRCPC;

At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, participated in a debate on the benefits of minimal residual disease testing in multiple myeloma treatment.

At the 2023 Lymphoma, Leukemia &...

01/19/2024

Lymphoma, Leukemia & Myeloma Network

Jeffrey Matous, MD, Sarah Cannon Research Institute

Conference Coverage

Talquetamab Plus Pomalidomide Shows Promising Efficacy, Manageable Safety for Patients With MM

01/11/2024

Jeffrey Matous , MD;

At the 65th ASH Annual Meeting, Jeffrey Matous, MD, shared initial trial results that talquetamab plus pomalidomide demonstrated rapid, deep responses among patients with R/R multiple myeloma and ≥2 prior lines of therapy.

At the 65th ASH Annual Meeting,...

01/11/2024

Oncology

Robert Rifkin, MD, Rocky Mountain Cancer Centers

Conference Coverage

Analyzing Outpatient Administration and Step-Up Dosing of Teclistamab Among Patients With Multiple Myeloma

01/05/2024

Robert M. Rifkin , MD, FACP;

At the 65th American Society of Hematology Annual Meeting in San Diego, California, Robert M Rifkin, MD, discusses a study analyzing the outpatient administration of step-up doses of BCMA-targeting bispecific antibody teclistamab.

At the 65th American Society of...

01/05/2024

Oncology

Section Editor

Shaji Kumar, MD

Mayo Clinic, Rochester, Minnesota

Multiple Myeloma Excellence Forum

Section Editor

Specialties

Events

Year Round Education

HMP Global Products